About this episode
In this episode, Melissa Butterworth discusses the state of the lab market in 2024. She highlights two major trends: larger transactions and hospital outreach transactions. She also mentions the continued interest and deals in the pathology space and the positive sign of mid-sized clinical lab transactions. Melissa provides insights into the multiples for pathology and clinical laboratory deals and emphasizes the importance of having a M&A advisor. Overall, she concludes that it is a positive time for lab owners considering exiting the space.
Get every episode summarized
Each time The End Game publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
